Morning Overview on MSN
The Ozempic breast-cancer benefit held even after researchers accounted for weight loss
Millions of women taking semaglutide or similar GLP-1 receptor agonists for diabetes and obesity now have a new data point to ...
Morning Overview on MSN
Ozempic-style drugs were linked to about 30% lower breast-cancer odds in a 111,000-woman study
Researchers at the University of Pennsylvania analyzed data from 111,646 women and found that those who used GLP-1 receptor ...
A new study suggests the investigational Stockholm3 blood test may improve the early detection of aggressive prostate cancer ...
UK MHRA validates Eisai's application for marketing approval of cancer drug taletrectinib: Tokyo Saturday, June 27, 2026, 10:00 Hrs [IST] Eisai Co., Ltd., has announced that the M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results